Certara (NASDAQ:CERT) Issues FY 2024 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.410-0.460 for the period, compared to the consensus estimate of 0.430. The company issued revenue guidance of $385.0 million-$400.0 million, compared to the consensus revenue estimate of $390.6 million. Certara also updated its FY24 guidance to $0.41-0.46 EPS.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CERT. KeyCorp decreased their price objective on shares of Certara from $23.00 to $20.00 and set an overweight rating for the company in a report on Thursday. Barclays decreased their price target on shares of Certara from $18.00 to $16.00 and set an equal weight rating for the company in a research note on Friday, June 28th. Finally, JMP Securities reissued a market perform rating on shares of Certara in a report on Wednesday. Seven analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of Hold and a consensus price target of $19.44.

Certara Trading Up 8.9 %

Shares of CERT stock opened at $15.12 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.26 and a quick ratio of 3.26. The business has a 50-day moving average of $15.53 and a 200 day moving average of $16.69. The stock has a market capitalization of $2.43 billion, a PE ratio of -38.77, a P/E/G ratio of 4.93 and a beta of 1.52. Certara has a 1-year low of $11.81 and a 1-year high of $19.87.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. The firm had revenue of $96.65 million during the quarter, compared to analysts’ expectations of $94.48 million. As a group, sell-side analysts anticipate that Certara will post 0.28 earnings per share for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.